Intensity Therapeutics, Inc. (INTS) was granted a 180‑day extension by Nasdaq to regain compliance with the exchange’s minimum $1.00 bid‑price requirement, extending the deadline to June 1 2026.
Under Nasdaq Listing Rule 5550(a)(2), a company must maintain a closing bid price of at least $1.00 for ten consecutive business days by the specified deadline; failure to do so results in delisting from the Nasdaq Capital Market, which would severely limit liquidity and access to capital.
The extension follows a prior 180‑day extension granted on June 6 2025. As of December 5 2025, INTS shares were trading between $0.46 and $0.51, well below the required threshold.
Intensity Therapeutics is a late‑stage biotechnology company focused on intratumoral cancer therapies. Its lead candidate, INT230‑6, is in a Phase 3 trial for metastatic sarcoma (INVINCIBLE‑3) and a Phase 2 program for triple‑negative breast cancer (INVINCIBLE‑4). Positive Phase 1/2 data showed a 75% disease‑control rate and a median overall survival of 11.9 months in advanced‑cancer patients.
Financially, the company reported $7.1 million in cash and cash equivalents as of September 30 2025, a debt‑to‑equity ratio of 0 % and a current ratio of 3.6, indicating strong liquidity and no debt burden. Capital raises have extended the cash runway into the second half of 2026 and into Q1 2027.
Management has stated it will actively monitor the closing bid price and take all appropriate actions to cure the deficiency, including share‑price support measures or a capital raise. The extension provides a critical window to implement these strategies.
The extension underscores the regulatory risk that Intensity faces; achieving a sustained $1.00 bid price by June 1 2026 is essential to maintain its Nasdaq listing, preserve liquidity, and support future capital‑raising efforts. Failure to meet the requirement would trigger delisting and significantly constrain the company’s ability to fund its clinical pipeline.
In summary, Intensity Therapeutics must leverage its clinical progress and financial position to raise its share price within the extended period, ensuring continued compliance and protecting investor confidence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.